-572 G/C single nucleotide polymorphism of XXXX and @entity295 predisposition in @entity740 .

@entity1 @entity650 @entity295 @entity740 @entity15146 @entity281 @entity15147 @entity65
UNASSIGNED: Single nucleotide polymorphisms (SNPs) of @entity650 are associated with the development of @entity740 ( @entity740 ). Their impact for @entity295 in the field of @entity740 was investigated. One control cohort of 115 @entity1 with @entity740 without @entity281 and another case cohort of 198 @entity1 with @entity740 and @entity295 were enrolled. Genotyping at the -174 ( @entity15147 ) and -572 positions of @entity650 ( @entity15146 ) was done by restriction fragment length polymorphism. Circulating @entity650 was measured by an enzyme immunoassay. The GG genotype of @entity15146 was more frequent among cases (78.3  %) than controls (62.6  %). No difference in the genotype frequencies of @entity15147 between cases and controls were found. Odds ratio for @entity295 was 2.07 (95%CI 1.24-3.44, p   =   0.005) with the GG genotype of @entity15146 , which was confirmed by logistic regression analysis taking into consideration the presence of chronic comorbidities. All-cause mortality until day 28 was similar between @entity1 with the GG genotype and the GC/CC genotypes of @entity15146 , but death caused from cardiovascular events not-related with @entity281 was more frequent with the GG genotype (14.6  % vs 2.4  %, p   =   0.031). Circulating @entity650 was greater among @entity1 of the GC/CC genotypes of @entity15146 and multiple organ dysfunction (p   =   0.013). The GG genotype of @entity15146 predisposes to @entity295 in @entity740 and to 28-day mortality by @entity295 -unrelated @entity65 .
